Noxopharm Ltd. · ASX:NOX
Noxopharm — Switzer Small & Micro Cap Virtual Investor Day (March 2021)
12 slides from Noxopharm's conference presentation, March 2021
Slide 1: Noxopharm Limited (ASX:NOX) Switzer Small & Micro Cap Virtual Investor Day
Noxopharm Limited (ASX:NOX) SWITZER SMALL & MICRO CAP VIRTUAL INVESTOR DAY March 2021 Discover Develop Dr Graham Kelly CEO and Managing Director Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 2: Disclaimer
Disclaimer This presentaKon has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectaKons reflected in the forward looking statements be considered as an offer or invitaKon to subscribe for, or purchase any shares in NOX, or as an include
Slide 3: Noxopharm is building a pipeline of drugs based on a unique proprietary technology platform
Noxopharm is building a pipeline of drugs based on a unique and proprietary technology plaGorm for the treatment of cancer and sepHc shock Of est. 55 million deaths globally from disease: • ~ 10 million are from cancer* • ~ 10 million are from septic shock* Tissue injury from: • Viral/bacterial infe
Slide 4: Link between cancer and septic shock
Link between Both involve abnormal immune cancer and and inflammatory sepHc shock responses Common Cancer: underlying • Manipulates the immune system to avoid immune aRack mechanism is • Increases inflammaHon to enable growth and spread altering balance between ceramide and Septic shock: sphingosine-1
Slide 5: Veyonda breakthrough COLD to HOT effect
Veyonda® breakthrough COLD to HOT effect C Majority of human tumours are COLD (lacking A immune cells) Converting COLD tumors to HOT means that standard anti-cancer treatments should work N better C Veyonda being developed as a combination drug to boost effectiveness of common cancer E treatments R V
Slide 6: Veyonda cancer: DARRT, LuPIN and IONIC programs
Veyonda® Two clinical studies confirm anH-cancer boost. 3rd key study now underway DARRT program • Veyonda + (low-dose) external beam radiotherapy (EBRT) C • • Phase I study / 25 men / end-stage prostate cancer CombinaHon delivers major boost to anH-cancer effect of EBRT1 A N LuPIN program • Veyonda +
Slide 7: Veyonda: potential treatment of cytokine release syndrome
Veyonda® Breakthrough potenHal treatment of cytokine release syndrome S Virus causes lung damage E Pre-clinically Veyonda blocks clorng P excessive T cytokine lung response Excessive release of I inflammatory cytokines damage shock C kidney damage S Cytokine release syndrome H (‘cytokine storm’) hear
Slide 8: Veyonda: NOXCOVID-1 clinical study ongoing
Veyonda® NOXCOVID-1 clinical study ongoing • 40 paKents with moderate COVID-19 disease S • Requiring hospitalizaKon and low-volume oxygen E supplementaKon P • Dose-escalaKon arm (400-1800 mg) complete • Dose-expansion arm (1800 mg) ongoing T I NOXCOVID program ObjecHve: to demonstrate that Veyonda C
Slide 9: Summary
SUMMARY Both DARRT and LuPIN have provided clear evidence of proof-of-concept IONIC trial The objecKve of this trial is to use Veyonda to overcome resistance of most cancers to anK-cancer drug Opdivo® (Bristol Myers Squibb) currently with annual sales of USD8 billion Veyonda is well tolerated as a c
Slide 10: Our commercial end-point for Veyonda
Our commercial end-point for Veyonda Noxopharm prepared to take Veyonda all the way to market. However, opportunity as a general booster of most forms of cancer therapy seen as being so large that a partnership potentially is more likely Currently working with Novartis (USD 200 B) and Bristol Myers
Slide 11: Key metrics
Key metrics as at 25 March 2021 Market cap A$182m News Flow (next 6 months) • IONIC-1 and DARRT-2 start paKent recruitment Share price A$0.66 • COVID-19 clinical trial compleKon • Growing first-in-class drug pipeline Issued cap 278.9m shares • Pharmorage (subsidiary) progressing novel drug developmen
Slide 12: For further information
For further informa2on email: info@noxopharm.com web: www.noxopharm.com twiRer: @noxopharm Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 12
Noxopharm — Switzer Small & Micro Cap Virtual Investor Day (March 2021) on 6ix